QR Kod

Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance

<b>Background:</b> Olaparib and niraparib are poly (ADP-ribose) polymerase inhibitors (PARPi) used primarily for the treatment of ovarian cancer. While both drugs have demonstrated efficacy in clinical trials, their safety profiles, particularly in real-world clinical settings, remain to be fully el...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Desirèe Speranza, Fausto Omero, Vincenzo Cianci, Mariapia Marafioti, Carla Infurna, Patrizia Carroccio, Edoardo Spina, Maria Antonietta Barbieri, Emanuela Esposito, Nicola Silvestris, Mariacarmela Santarpia
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI AG 2025-04-01
Seri Bilgileri:Pharmaceuticals
Konular:
olaparib
niraparib
EudraVigilance
pharmacovigilance
PARP inhibitors
real-world data
Online Erişim:https://www.mdpi.com/1424-8247/18/4/528
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller